期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

荧光实时定量PCR方法在肺癌相关基因检测中的应用 被引量：1

Clinical value of real-time quantitative fluorescent PCR on lung cancer genetic testing
下载PDF
导出
摘要 目的研究实时定量荧光PCR在非小细胞肺癌患者肿瘤组织、正常组织及外周血中RRM1、ERCC1表达水平检测的应用价值。方法构建目的基因质粒标准品,运用PCR仪进行SYBR荧光实时定量分析,比较其表达水平。结果两者在外周血中表达水平与TNM分期、是否淋巴转移等有关;肿瘤组织和外周血中的表达具有一致性。结论荧光实时定量PCR具有良好的特异性和灵敏度,费用低,操作简便,可应用于临床检验工作。 Objective To study the detection value of real-time quantitative PCR on the expression of RRMI and ERCC1 in patients with non-small cell lung cancer tumor tissue, normal tissue and peripheral blood. Methods The expression of RRMI and ERCCI was measured by SYBR real time analysis through PCR. Results Their ex- pression in the peripheral blood was associated with TNM stage and lymph node metastasis. The expression in tumor tissue and peripheral blood was consistent. Conclusion Real-time PCR has the advantages of high specificity and sensitivity, low cost, and easy operation.
作者 陈鑫
机构地区 中国人民解放军
出处 《临床肺科杂志》 2014年第1期81-84,共4页 Journal of Clinical Pulmonary Medicine
关键词 非小细胞肺癌 实时定量荧光PCR RRM1 ERCC1 non-small cell lung cancer quantitative real -time fluorescence PCR RRMI ERCC1
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献47

  • 1Ceppi, P., Volante, M., Novello, S., Rapa, I., Danenberg, K.D., Danenberg, P.V., Cambieri, A., Selvaggi, G., Saviozzi, S., Calogero, R., et al., 2006. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oneol., 17(12):1818-1825. [doi:10. 1093/annonc/mdl300].
  • 2Davidson, J.D., Ma, L., Flagella, M., Geeganage, S., Gelbert, L.M., Slapak, C.A., 2004. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res., 64(11):3761-3766. [doi:10.1158/ 0008-5472.CAN-03-3363].
  • 3Dong, S., Guo, A.L., Chen, Z.H., Wang, Z., Zhang, X.C., Huang, Y., Xie, Z., Yan, H.H., Cheng, H., Wu, Y.L., 2010 RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J. Hematol. Oncol., 3(1):10. [doi:10.1186/1756-8722-3-10].
  • 4Gautam, A., Li, Z.R., Bepler, G., 2003. RRMl-induced metastasis suppression through PTEN-regulated pathways. Oncogene, 22(14):2135-2142. [doi:10.1038/sj.onc.1206 232].
  • 5Goan, Y.G., Zhou, B., Hu, E., Mi, S., Yen, Y., 1999. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res., 59(17):4204-4207.
  • 6Isla, D., Sarries, C., Rosell, R., Alonso, G., Domine, M., Taron, M., Lopez-Vivanco, G., Camps, C., Botia, M., Nunez, L., et al., 2004. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small- cell lung cancer. Ann. OncoL, 15(8):1194-1203. [doi:10. 1093/annonc/mdh319].
  • 7Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Thun, M.J., 2007. Cancer statistics, 2007. CA Cancer J. Clin., 57(1): 43-66. [doi: 10.3322/canjclin.57.1.43].
  • 8Quinn, J.E., Kennedy, R.D., Mullan, P.B., Gilmore, P.M., Carty, M., Johnston, P.G., Harkin, D.P., 2003. BRCA1 functions as a differential modulator of chemotherapyinduced apoptosis. Cancer Res., 63(19):6221-6228.
  • 9Quinn, J.E., James, C.R., Stewart, G.E., Mulligan, J.M., White, P., Chang, G.K., Mullan, P.B., Johnston, P.G., Wilson, R.H., Harkin, D.P., 2007. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin. CancerRes., 13(24):7413-7420. [doi :10.1158/1078-0432.CCR-07-1083].
  • 10Rosell, R., Scagliotti, G., Danenberg, K.D., Lord, R.V., Bepler, G., Novello, S., Cooc, J., Crino, L., Sanchez, J.J., Taron, M., et al., 2003. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene, 22(23):3548-3553. [doi:l 0.1038/ sj.onc.1206419].

共引文献23

同被引文献15

引证文献1

临床肺科杂志
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部